Marinomed Biotech AG Email Format

Biotechnology ResearchAustria11-50 Employees

Marinomed Biotech AG is an Austrian, science-driven biotech company with a growing development pipeline and globally marketed therapeutics. The Company focuses on the development of innovative, patent-protected products in the therapeutic areas of respiratory and ophthalmic diseases, based on the proprietary Marinosolv® platform. 

The Marinosolv® technology significantly improves the solubility and bioavailability of hardly soluble compounds, enabling the development of novel therapies for immune-related and inflammatory disorders. Under the brand Solv4U Marinomed offers  drug development in all stages, based on its patent protected Marinosolv® technology platform. 

The Company’s Carragelose®-based OTC business was successfully sold to Unither Pharmaceuticals in 2025 

Headquartered in Korneuburg, Austria, Marinomed is listed on the standard market of the Vienna Stock Exchange (VSE:MARI). 

https://www.marinomed.com/en/data-protection-declaration
https://www.marinomed.com/en/legal-notice

Sign up for free to view info

Company overview Employee directory